» Articles » PMID: 34187420

Telemedical Care and Quality of Life in Patients with Schizophrenia and Bipolar Disorder: Results of a Randomized Controlled Trial

Overview
Journal BMC Psychiatry
Publisher Biomed Central
Specialty Psychiatry
Date 2021 Jun 30
PMID 34187420
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Schizophrenia and bipolar disorder are serious psychiatric disorders with a high disease burden, a high number of years of life lived with disability and a high risk for relapses and re-hospitalizations. Besides, both diseases are often accompanied with a reduced quality of life (QoL). A low level of quality of life is one predictor for relapses. This study examines whether a telemedical care program can improve QoL.

Methods: Post stationary telemedical care of patients with severe psychiatric disorders" (Tecla) is a prospective controlled randomized intervention trial to implement and evaluate a telemedical care concept for patients with schizophrenia and bipolar disorder. Participants were randomized to an intervention or a control group. The intervention group received telemedical care including regular, individualized telephone calls and SMS-messages. QoL was measured with the German version of the WHOQOL-BREF. Effects of telemedicine on QoL after 6 months and treatment*time interactions were calculated using linear regressions (GLM and linear mixed models).

Results: One hundred eighteen participants were recruited, thereof 57.6% men (n = 68). Participants were on average 43 years old (SD 13). The treatment*time interaction was not significant. Hence, treatment had no significant effect either. Instead, gender is an influencing factor. Further analysis showed that social support, the GAF-level and QoL-values at baselines were significant determinants for the improvement of QoL.

Conclusion: The telemedicine care concept Tecla was not significant for QoL in patients with severe psychiatric disorders. More important for the QoL is the general social support and the level of global functioning of the patients.

Trial Registration: German Clinical Trials Register, DRKS00008548, registered 21 May 2015 - retrospectively registered, https://www.drks.de/drks_web/setLocale_EN.do.

Citing Articles

Leveraging Personal Technologies in the Treatment of Schizophrenia Spectrum Disorders: Scoping Review.

DArcey J, Torous J, Asuncion T, Tackaberry-Giddens L, Zahid A, Ishak M JMIR Ment Health. 2024; 11:e57150.

PMID: 39348196 PMC: 11474131. DOI: 10.2196/57150.


Exploring the interplay of psychiatric symptoms, antipsychotic medications, side effects, employment status, and quality of life in Chronic Schizophrenia.

Zhou D, Yang X, Wang W, Jin W, Tang Y, Zheng Z BMC Psychiatry. 2024; 24(1):484.

PMID: 38956530 PMC: 11220993. DOI: 10.1186/s12888-024-05929-3.


The preferences for the telemedicine and standard health care services from the perspective of the patients with schizophrenia.

Li M, Chen Y, Hu X, Wang S BMC Psychiatry. 2023; 23(1):361.

PMID: 37226168 PMC: 10210282. DOI: 10.1186/s12888-023-04885-8.


Evidence of Phone vs Video-Conferencing for Mental Health Treatments: A Review of the Literature.

Chen P, Helm A, Caloudas S, Ecker A, Day G, Hogan J Curr Psychiatry Rep. 2022; 24(10):529-539.

PMID: 36053400 PMC: 9437398. DOI: 10.1007/s11920-022-01359-8.


Remote Patient Monitoring for Neuropsychiatric Disorders: A Scoping Review of Current Trends and Future Perspectives from Recent Publications and Upcoming Clinical Trials.

Sakamaki T, Furusawa Y, Hayashi A, Otsuka M, Fernandez J Telemed J E Health. 2022; 28(9):1235-1250.

PMID: 35073206 PMC: 9508442. DOI: 10.1089/tmj.2021.0489.

References
1.
Moher D, Schulz K, Altman D . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001; 285(15):1987-91. DOI: 10.1001/jama.285.15.1987. View

2.
Ben-Zeev D, Brian R, Jonathan G, Razzano L, Pashka N, Carpenter-Song E . Mobile Health (mHealth) Versus Clinic-Based Group Intervention for People With Serious Mental Illness: A Randomized Controlled Trial. Psychiatr Serv. 2018; 69(9):978-985. DOI: 10.1176/appi.ps.201800063. View

3.
Brissos S, Dias V, Carita A, Martinez-Aran A . Quality of life in bipolar type I disorder and schizophrenia in remission: clinical and neurocognitive correlates. Psychiatry Res. 2008; 160(1):55-62. DOI: 10.1016/j.psychres.2007.04.010. View

4.
Jakobsen J, Gluud C, Wetterslev J, Winkel P . When and how should multiple imputation be used for handling missing data in randomised clinical trials - a practical guide with flowcharts. BMC Med Res Methodol. 2017; 17(1):162. PMC: 5717805. DOI: 10.1186/s12874-017-0442-1. View

5.
Ben-Zeev D, Brenner C, Begale M, Duffecy J, Mohr D, Mueser K . Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia. Schizophr Bull. 2014; 40(6):1244-53. PMC: 4193714. DOI: 10.1093/schbul/sbu033. View